Streetwise Articles
Gold Co.'s Stock Price Has Taken a 'Startling Drop'
Source: Clive Maund (8/2/22)
Expert Clive Maund shares the recent drop in Getchell Gold Corp.'s stock price and his rating of the company in light of the news.
More >
Expert Says Biotech Co. Is a âStrong Buyâ After Phase 2 Study
Source: Clive Maund (8/2/22)
Expert Clive Maund gives his assessment of biotech Algernon Pharmaceuticals Inc. after its Phase 2 study of Ifenprodil.
More >
Expert Rates Mining Co. A 'Strong Speculative Buy'
Source: Clive Maund (8/2/22)
Expert Clive Maund shares his assessment of Omineca Mining and Metals Ltd. since its stock is currently inexpensive, and tells you whether he believes this stock is a Buy or a "goodbye."
More >
Expert Believes Health Co. Blooms With Opportunity
Source: Clive Maund (8/2/22)
Expert Clive Maund touches on the latest news with Bloom Health Partners Inc. from the enthusiastic buying toward the end of June to whether he believes the health company is still bullish.
More >
Tech Co. âRight at the Point of Breakout'
Source: Clive Maund (8/2/22)
BioLargo Inc. seemed to be very close to breaking out of its tight trading range on July 20, 2022, after remaining in the same place for a month. Expert Clive Maund goes over this update and his assessment of the company after this news.
More >
Turn-Key Solar Provider Adds Record Number of Clients in Q2
Source: Streetwise Reports (8/2/22)
SunPower Corp. shares traded over 9% higher after the company reported Q2/22 financial results highlighting a 63% YoY increase in revenue. The firm confirmed its previous guidance indicating that it expects to add 73,000 to 80,000 net new customers in FY/2022.
More >
EV Co. Buys Romeo Power To Bring Battery Production In-House
Source: Streetwise Reports (8/1/22)
Shares of lithium-ion battery manufacturer Romeo Power Inc. traded 26% higher after the company reported it entered into a definitive agreement to be acquired by commercial EV truck maker Nikola Corp. in an all-stock transaction valued at $144 million.
More >
Study Review Shows Greater Promise for Biopharma Co.'s Cough Treatment
Source: Andre Uddin (8/1/22)
After Algernon Pharmaceuticals Inc.'s Ifenprodil treatment for chronic cough was reviewed in a Phase 2 analysis, analysts at Research Capital Corp. noted that it is maintaining its Speculative Buy rating on the company.
More >
Argentina Lithium Active At Salar De Rincon
Source: The Critical Investor (7/30/22)
The Critical Investor takes a look at one junior lithium play in Argentina that just had some success with the drill bit and is building its prospective land package â real estate that should only increase in value as lithium carbonate prices hover around US$75,000 per tonne.
More >
Drug Candidate Repairs Motor/Sensory Function in Stroke
Source: Streetwise Reports (7/29/22)
Shares of NervGen Pharma Corp. traded 28% higher yesterday after the company reported that, in a landmark pre-clinical animal study, its NVG-291-R demonstrated significant functional repair to damage from ischemic stroke seven days following the event.
More >
Oil & Gas Services Co. Posts 90% Increase in Q2 Revenues
Source: Streetwise Reports (7/29/22)
Energy industry service company Mammoth Energy Services Inc.'s shares traded 22% higher after the company reported Q2/22 financial results that included significant increases in quarterly revenue, net income, and adjusted EBITDA.
More >
Energy Co. Looks for Cash Producing Oil & Gas Assets in Africa
(7/29/22)
Tenaz Energy Corp. reported it was unsuccessful in obtaining the number of votes needed from SDX Energy Plc.'s shareholders to acquire the company. The firm continues to search for other oil and gas assets to acquire in North Africa and the Middle East that are congruent with its high free cash flow generation strategy. Research Capital Corp. advised in a research note that it is maintaining its Speculative Buy rating and CA$5.00 Target Price on the company.
More >
Val-dâOr Junior Finds Anomalies at MoGold
Source: Streetwise Reports (7/28/22)
Geophysical surveys often reveal secrets just below the surface. One junior explorer operating in Quebecâs prolific Val dâOr mining camp has found a few of those secrets and itâs ready to drill them to see if a secret or two could become something much more valuable.
More >
Junior Says ESG Is More Than an Acronym
Source: Streetwise Reports (7/28/22)
This junior is trying new ways to involve the local population in its project, hoping to take âenvironmental, social, and governanceâ considerations to a new level.
More >
Junior Hits High-Grade Silver in Colombia
Source: Streetwise Reports (7/28/22)
Outcrop Silver & Gold Corp., on its way to a maiden resource estimate at its Colombian flagship project, says it has returned its thickest and highest-grade intercepts yet.
More >
Additional Study Review Reveals Patients Coughed Much Less
Source: Streetwise Reports (7/28/22)
A scientist at a junior biotech company recently conducted an additional review of the top line data from a Phase 2a study that used NP-120 to treat idiopathic pulmonary fibrosis (IPF) and chronic cough â only to learn that it treated chronic cough far better than first thought.
More >
Biotech Co. Granted New Patent for Breast Cancer Vaccine
(7/27/22)
Last Thursday, Anixa Biosciences Inc. announced that the USPTO granted an extension for the firm's patented breast cancer vaccine technology. H.C. Wainwright & Co. LLC advised that this action strengthens the company's IP portfolio and therefore it is reiterating its Buy rating on Anixa.
More >
Miner to Finance Alaska Project with $60M Royalty Deal
Source: Streetwise Reports (7/27/22)
Shares of Northern Dynasty Minerals Ltd. traded more than 22% higher after the Vancouver mining firm reported it entered into a life-of-mine royalty agreement for non-core metals which may provide up to $60 million in proceeds.
More >
Biopharma Co. Signs Exclusive License Deal for Ricin Antigen
Source: Streetwise Reports (7/27/22)
Shares of Soligenix Inc. traded 8% higher after the company reported it formed a strategic global partnership to supply SERB Pharmaceuticals with its novel ricin antigen for use in developing a therapeutic treatment against ricin poisoning.
More >
Biomedical Firms Merger Makes Programming Cells Easier
Source: Streetwise Reports (7/26/22)
Shares of Zymergen Inc. traded 16% higher after the company reported it agreed to be acquired by Ginkgo Bioworks Inc. in an all-stock transaction valued at $300 million.
More >
Cancer Co.'s Price Target Adjusted After Reverse Stock Split
(7/25/22)
Late clinical-stage biopharmaceutical company Cellectar Biosciences Inc. very recently underwent a one for 10 reverse stock split. ROTH Capital Partners LLC advised that it has adjusted its forward projections for the firm and adjusted its 12-month price target to $40/share.
More >
Franco and Royal Make Major Investments
Source: Adrian Day (7/25/22)
Expert Adrian Day discusses recent purchases from two royalty companies, as well as preliminary quarterly reports from several gold companies that he considers top buys right now.
More >
Radiotherapy Co. On-Track With Two Clinical Trials
(7/24/22)
Plus Therapeutics Inc. is developing novel radiotherapy treatments for several rare cancer targets including glioblastoma and leptomeningeal metastases. H.C. Wainwright & Co. advised in a research note that it is reiterating its Buy rating on the company as it expects that upcoming data from two key trials for the firm's RNL-based treatments could provide a major catalyst for the stock in H2/22.
More >
Pro Athlete Benefits From Co.'s Wound Treatment Device
Source: Streetwise Reports (7/22/22)
Shares of SANUWAVE Health Inc. traded 12% higher after the company reported it successfully treated legendary football player Jim McMahon Jr. with its ENERGY FIRST system.
More >
Medical Device Firm Maintains Growth Momentum in Q2/22
(7/21/22)
electroCore Inc.'s Q2/22 and H1/22 revenues are up quarter over quarter and year over year, respectively, and the upward trend is expected to continue through year-end 2022, noted an H.C. Wainwright & Co. report.
More >
